PHENOTYPIC DETECTION OF CARBAPENEMASE PRODUCTION AMONG GRAM NEGATIVE BACILLI BY MODIFIED CARBAPENEM INACTIVATION METHOD

K.M. JINSHA¹, R. JOSE²*, C. VALSAN³, K.A. SATHIAVATHY^4
1School of Health Sciences, University of Calicut, Malappuram, 673 635, Kerala, India
²Department of Microbiology, Jubilee Mission Medical College & Research Centre, Thrissur, 680005, Kerala, India
³Department of Microbiology, Jubilee Mission Medical College & Research Centre, Thrissur, 680005, Kerala, India
⁴Department of Microbiology, Jubilee Mission Medical College & Research Centre, Thrissur, 680005, Kerala, India
* Corresponding Author : rosdinmi@gmail.com

Received : 02-11-2019     Accepted : 26-11-2019     Published : 30-11-2019
Volume : 11     Issue : 11       Pages : 1736 - 1738
Int J Microbiol Res 11.11 (2019):1736-1738

Keywords : mCIM, CLSI
Academic Editor : Abdel Raheem M.A., Palaksha M.N., Dey S., Sharanya K., Sodani Sadhna
Conflict of Interest : None declared
Acknowledgements/Funding : Authors are thankful to Department of Microbiology, Jubilee Mission Medical College & Research Centre, Thrissur, 680005, Kerala, India
Author Contribution : All authors equally contributed

Several phenotypic methods for detection of carbapenemase producing isolates have been developed and used in clinical microbiology laboratories and all existing methods have limitations. Modified Carbapenem Inactivation (mCIM) method is a new growth-based assay recommended by CLSI for the detection of carbapenemases. In this study we performed mCIM for 129 meropenem resistant Gram negative bacilli (E.coli =20, K. pneumoniae= 55, P.aeruginosa = 13 and A.baumannii = 41). Hundred and one (78.3%) isolates were positve, 23 (17.8%) were negative and five isolates gave indeterminate results in mCIM. We found out that mCIM is an easy and inexpensive method for detection of carbapenemase production among Gram negative bacilli.

1. Livermore D.M. (2012) Korean J Intern Med., 27, 128-142.
2. Canton R., Akova M., Carmeli Y., Giske C.G., Glupczynski Y., Gniadkowksi M., et al. (2012) Clin Microbiol Infect., 18, 413-431.
3. Karah N., Sundsfjord A., Towner K., Samuelsen O. (2012) Drug Resist Updat., 15, 237-247.
4. Clinical and Laboratory Standards Institute (2018) 28th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Girlich D., Poirel L., Nordmann P. (2012) J Clin Microbiol., 50,477-9.
6. Anderson K.F., Lonsway D.R., Rasheed J.K., Biddle J., Jensen B., McDougal L.K., et al. (2007) J Clin Microbiol., 45,2723-25
7. Carvalhaes C.G., Picao R.C., Nicoletti A.G., Xavier D.E., Gales A.C. (2010) J Antimicrob Chemother., 65,249-51.
8. Vasoo S., Cunningham S.A., Kohner P.C., Simner P.J., Mandrekar J.N., Lolans K., Hayden M.K., Patel R. (2013) J Clin Microbiol., 51,3097-101.
9. Sun K., Xu X., Yan J., Zhang L. (2017) Ann Lab Med., 37,305-312.
10. Van der Zwaluw K., de Haan A., Pluister G.N., Bootsma H.J., de Neeling A.J., Schouls L.M. (2015) PLoS One, 10,0123690.
11. Swaminathan A., Ardra M., Manoharan A., Nair K.P., Girija K.R. (2016) J Acad Clin Microbiol., 18,100-4
12. Wattal C., Goel N., Oberoi J., Raveendran R., Datta S., Prasad K. (2010) J Asso Physicians India, 58 Suppl., 32-6.
13. Gupta E., Mohanty S., Sood S., Dhawan B., Das B.K., Kapil A. (2006) Indian J Med Res.,124,95-8.
14. Datta S., Wattal C., Goel N., Oberoi J.K., Raveendran R., Prasad K.J. (2012) Indian J Med Res.,135(6),907-912.
15. Sekar R., Srivani S., Amudhan M., Mythreyee M. (2016) Indian J Med Res.,144, 781-3.
16. Treatment guidelines for antimicrobial use in common syndromes. New Delhi, India: Indian Council of Medical Research, Department of Health Research; 2017.
17. Pierce V.M., Simner P.J., Lonsway D.R., Roe-Carpenter D.E., Johnson J.K., Brasso W.B., Bobenchik A.M., et al. (2017) J Clin Microbiol., 55,2321-2333.
18. Simner P.J., Johnson J.K., Brasso W.B., Anderson K., Lonsway D.R., Pierce V.M., et al. (2018) J Clin Microbiol., 56,1369.